Illuccix FDA Approval History
FDA Approved: Yes (First approved December 17, 2021)
Brand name: Illuccix
Generic name: gallium Ga 68 gozetotide
Dosage form: Injection Kit
Company: Telix Pharmaceutical, Inc.
Treatment for: Positron Emission Tomography Imaging
Illuccix (gallium Ga 68 gozetotide) is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
Illuccix is indicated for PET of PSMA positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- for selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated.
Development timeline for Illuccix
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
